Comparison of iodine-123-vasoactive intestinal peptide receptor scintigraphy and indium-111-CYT-103 immunoscintigraphy.
Recently, we have shown that the expression of receptors for vasoactive intestinal peptide (VIP) on intestinal adenocarcinomas can be used for in vivo targeting of primary or metastatic tumor sites using 123I-labeled VIP. Several other receptors and antigens including the TAG-72 protein have also been implemented for in vivo localization purposes. In this study, we have compared the in vitro and in vivo binding of 123I-VIP and of the 111In-labeled monoclonal antibody (MAb) directed against TAG-72 (OncoScint; 111In-CR-103) in patients with intestinal adenocarcinomas in a single-blinded, prospectively randomized trial.


METHODS
Twenty patients were administered either 123I-VIP (150-200 MBq; 1 microgram) or 111In-CYT-103 (150 MBq; 1 mg) for one imaging study. After interim analysis demonstrated superior imaging with 123I-VIP, the next 10 patients (accounting for a total of 50 patients) enrolled in this trial underwent both studies in random order to allow for a direct comparison.


RESULTS
In total, 123I-VIP scans were true-positive in 28 of 30 patients (93%) versus 17 of 30 patients administered 111In-CYT-103 (56%). In the subgroup of 10 patients enrolled in the second part of the study, primary intestinal adenocarcinomas were imaged in five of five patients with 123I-VIP and in only two of these patients with 111In-CYT-103. Liver metastases were visualized in five of six patients by 123I-VIP receptor scanning and in four of these patients with 111In-CYT-103. The in vitro results indicated significant binding of 123I-VIP to primary colorectal tumors as well as to HT29 and COLO320 adenocarcinoma cells. In vitro, adenocarcinoma cells also expressed abundant numbers of the TAG-72 antigen.


CONCLUSIONS
Intestinal adenocarcinomas co-express VIP receptors and the IAG-72 antigen. Despite significant in vitro binding of both agents, however, the VIP receptor scan is more sensitive in localizing intestinal adenocarcinomas and metastatic spread.
Raderer
M
M
Department of Nuclear Medicine, University of Vienna, Austria.
Becherer
A
A
Kurtaran
A
A
Angelberger
P
P
Li
S
S
Leimer
M
M
Weinlaender
G
G
Kornek
G
G
Kletter
K
K
Scheithauer
W
W
Virgolini
I
I
D000230:Adenocarcinoma / Q000000981:diagnostic imaging* / Q000556:secondary; D000911:Antibodies, Monoclonal; D005260:Female; D005770:Gastrointestinal Neoplasms / Q000000981:diagnostic imaging*; D006801:Humans; D007205:Indium Radioisotopes; D007457:Iodine Radioisotopes; D008113:Liver Neoplasms / Q000000981:diagnostic imaging / Q000556:secondary; D008297:Male; D008875:Middle Aged; D009842:Oligopeptides; D010190:Pancreatic Neoplasms / Q000000981:diagnostic imaging*; D004369:Pentetic Acid / Q000031:analogs & derivatives*; D011446:Prospective Studies; D016719:Radioimmunodetection; D018005:Receptors, Vasoactive Intestinal Peptide / Q000032:analysis*; D016037:Single-Blind Method; D014407:Tumor Cells, Cultured; D014660:Vasoactive Intestinal Peptide
D000911:Antibodies, Monoclonal; C063430:Indium 111In-satumomab pendetide; D007205:Indium Radioisotopes; D007457:Iodine Radioisotopes; D009842:Oligopeptides; D018005:Receptors, Vasoactive Intestinal Peptide; D014660:Vasoactive Intestinal Peptide; D004369:Pentetic Acid